“Dr. Seethamraju's statement on Oct 7 that the "
Post# of 148166
(Total Views: 527)
Posted On: 10/15/2020 5:43:05 PM
“Dr. Seethamraju's statement on Oct 7 that the "FDA is reviewing CD12 unblinded data" impacts the schedule if true.”
I thought the S/C data would only be reviewed by the FDA if the DSMB recommended that the trial be halted? What other reason would the FDA have to review the data?
I thought the S/C data would only be reviewed by the FDA if the DSMB recommended that the trial be halted? What other reason would the FDA have to review the data?
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼